Open AccessEndothelial Function, Fibrinolysis, and Angiotensin‐Converting Enzyme Inhibition
Author(s) -
Vaughan Douglas E.
Publication year - 1997
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/j.1932-8737.1997.tb00010.x
Subject(s) - fibrinolysis , medicine , renin–angiotensin system , angiotensin converting enzyme , angiotensin ii , ace inhibitor , endocrinology , pharmacology , receptor , blood pressure
Experimental and clinical studies with angiotensin‐converting enzyme (ACE) inhibitors have suggested that these agents may reduce the risk of atherothrombotic events. Recent studies have identified the role of angiotensin II and ACE in the regulation of fibrinolysis. There is now substantial evidence that the renin‐angiotensin system (RAS) plays an important role in the regulation of vascular fibrinolytic balance. This recently recognized relationship may contribute to the vasculoprotective effects of ACE inhibitors.